Kevin Nelson

IP Litigation

Partner

Kevin is an intellectual property attorney with a focus on large-scale complex patent infringement litigation. For more than 20 years, Kevin has guided clients through legal and regulatory challenges with a focus on the life sciences industry. He is a first-chair trial lawyer who has helped clients obtain approval to commercially market products under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. In addition to developing strategies for filing an abbreviated new drug application (ANDA), Kevin has represented clients in every phase of patent litigation and has successfully argued before the United States Court of Appeals for the Federal Circuit. His matters have involved patents purportedly covering well-known pharmaceutical products and methods for using those products. In the face of an evolving and uncertain biosimilar industry in the United States, Kevin has counseled clients on navigating the biosimilar legal and regulatory pathways. He also has successfully represented clients in inter partes review (IPR) proceedings.

Kevin advises clients on various corporate matters including mergers and acquisitions, due diligence evaluation, and corporate restructuring, and has served as outside general counsel for emerging companies. He counsels clients on regulatory matters before the U.S. Food and Drug Administration, such as opposing citizen petitions. Rounding out his experience, Kevin has handled cases involving trademark and copyright infringement, false or unfair advertising, and unfair competition claims.

Spanish and English

DePaul University College of Law, JD, 2001

Indiana University, BA, 1998